Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR

CONCLUSIONS: The findings of this study suggest both activity and safety for the combination of chemotherapy and the mTOR inhibitor everolimus (CT+EVE) in patients with HER2- mBC who have alterations in the PI3K pathway, particularly those who have received fewer prior chemotherapy. However, it is crucial to note that large-scale, randomized control studies are warranted to more comprehensively characterize the efficacy and safety of this combination therapy.PMID:38531793 | DOI:10.24976/Discov.Med.202436182.49

Source: Discovery Medicine - March 26, 2024 Category: Research Authors: Rong Wang Qiao-Yan Zhu Wei-Wu Ye Yuan Huang Zhan-Hong Chen Ya-Bing Zheng Xiao Zou Jian Wang Dan-Lu Jiang Xiao-Jia Wang Zheng-Yang Xu Wen-Ming Cao Source Type: research